Orpathys approved in China for patients with lung cancer and MET gene alterations
First-in-class approval in China in this setting and first regulatory approval for the oral, potent and highly selective MET tyrosine kinase inhibitorAstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the